Aging/Older Adults

The National Conference of State Legislatures recently released an article exploring different steps that states are taking to address the rapidly aging population and how to keep that population in their homes longer. The article looks at approaches from across the country exploring food security, financial support, transportation, housing, the direct care workforce, social isolation prevention, and more.

The Federal Communications Commission released guidance earlier this week permitting states and managed care plans to make calls, or robocalls, and send text messages under certain circumstances without violating federal law. The FCC’s ruling comes in response to a letter from the Secretary of the U.S. Department of Health and Human Services requesting an exception to the federal Telephone Consumer Protection Law as states reach out to enrollees to raise awareness of forthcoming Medicaid eligibility redeterminations. The federal guidance clarifies how states working with local government agencies and managed care companies may, under certain circumstances, make robo calls or send autodialed text messages

There are several changes that may affect SNAP household’s benefit amounts over the coming months. The temporary boost to SNAP benefits put in place during the COVID-19 pandemic, known as emergency allotments, will end nationwide after the February 2023 issuance. In addition, households that receive SNAP and Social Security benefits will see a decrease in their SNAP benefits because of the significant cost of living increase to Social Security benefits that took effect on Jan. 1, 2023.

The Centers for Disease Control and Prevention (CDC) released a fact sheet on how to protect older adults from Respiratory Syncytial Virus (RSV). RSV infections can be dangerous for older adults and those with chronic heart and lung disease, or those with weakened immune systems. The fact sheet reviews common symptoms, prevention methods, and more.

Paxlovid is an antiviral treatment for people with mild to moderate COVID-19 symptoms at high risk of becoming seriously ill, including adults 65 and up. It is important for older adults to consider a treatment plan before becoming infected, as Paxlovid could have complications with other drugs and should be evaluated by a medical provider. This article provides more information about Paxlovid and suggests ways older adults can prepare a treatment plan in advance of catching the new COVID-19 variant.

As part of the continuing efforts under President Biden’s initiative to improve nursing home transparency, safety and quality, and accountability, the U.S. Department of Health and Human Services announced new actions to reduce the inappropriate use of antipsychotic medications and to bring greater transparency about nursing home citations to families. Beginning this month, CMS will conduct targeted, off-site audits to determine whether nursing homes are accurately assessing and coding individuals with a schizophrenia diagnosis.

Elder financial exploitation threatens the financial security of millions of older Americans annually. CFPB has released updated resources for elder fraud prevention and response networks, including a report on the network collaboration and a streamlined virtual Network Development Guide.

Justice in Aging just released a new issue brief on the use of psychotropic medications in nursing facilities. The brief explores why reform initiatives have had limited success and the implications the use of psychotropic medications has on residents’ decision-making rights. In this installment of a series of issue briefs, Justice in Aging evaluates several proposals, and those proposals’ impacts on real-world residents.

The FDA recently granted accelerated approval for the drug Leqembi, a medication intended to slow the progression of Alzheimer’s disease. Leqembi, the brand name for lecanemab, is the second Alzheimer’s therapy for individuals with mild cognitive impairment. Lequembi targets the protein amyloid and can be prescribed to patients in early to mid-stages of Alzheimer’s disease. Eisai, the manufacturer of Leqembi, reports that the drug will be available by January 23, 2023 and estimates the cost of the biweekly infusion to be $26,500 annually. Medicare coverage of Leqembi and other drugs like it, such as Aduhelm, that have accelerated FDA approval are limited to beneficiaries enrolled in certain clinical trials.

This publication finds meaningful variation in disenrollment and churn across Medicaid beneficiary categories. Specifically, beneficiaries with Supplemental Security Income-related eligibility have low rates of disenrollment and high rates of reenrollments. In this research, Mathematica uses data from the Transformed Medicaid Statistical Information System Analytic File to examine rates of disenrollment, churn, and continuous coverage among categories of children and adult Medicaid beneficiaries whose eligibility is related to a disability.